Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RECTIV

« Back to Dashboard
Rectiv is a drug marketed by Forest Labs Inc and is included in one NDA. It is available from two suppliers.

The generic ingredient in RECTIV is nitroglycerin. There are thirty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the nitroglycerin profile page.

Summary for Tradename: RECTIV

Suppliers / Packagers: see list3

Pharmacology for Tradename: RECTIV

Drug ClassNitrate Vasodilator
Physiological EffectVasodilation

Clinical Trials for: RECTIV

Nitroglycerin in Non-small Cell Lung Cancer
Status: Recruiting Condition: Non Small Cell Lung Cancer (NSCLC)

Treatment of Suspected Cholelithiasis With Nitroglycerin
Status: Not yet recruiting Condition: COLIC; BILIARY TRACT DISEASES

GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy
Status: Recruiting Condition: Prostate Cancer

Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure
Status: Withdrawn Condition: Anal Fissure

Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter
Status: Completed Condition: Healthy

Investigation Into the Role of GTN & RIPC in Cardiac Surgery
Status: Recruiting Condition: Myocardial Reperfusion Injury

GOT-IT Trial: Glyceryl Trinitrate for Retained Placenta
Status: Recruiting Condition: Retained Placenta.

MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects
Status: Completed Condition: Healthy

The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas
Status: Completed Condition: Renal Failure

The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Status: Recruiting Condition: Contraception; Pain

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Inc
OINTMENT;INTRA-ANAL021359-001Jun 21, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn